Cargando…
Comparative review of the blood pressure-lowering and cardiovascular benefits of telmisartan and perindopril
Hypertension is a major cardiovascular (CV) risk factor, and blood pressure (BP)-lowering treatment substantially reduces the risk. This review compares the available clinical evidence from the BP-lowering and CV-outcome studies of telmisartan and perindopril, which are among the most intensively st...
Autores principales: | Wang, Ji-Guang, Pimenta, Eduardo, Chwallek, Frank |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3983078/ https://www.ncbi.nlm.nih.gov/pubmed/24741317 http://dx.doi.org/10.2147/VHRM.S59429 |
Ejemplares similares
-
Comparing the Neuroprotective Effects of Telmisartan, Perindopril, and Nebivolol Against Lipopolysaccharide-Induced Injury in Neuron-Like Cells
por: Şen, Selçuk, et al.
Publicado: (2022) -
Perindopril for improving cardiovascular events
por: DiNicolantonio, James J, et al.
Publicado: (2014) -
A Review of Perindopril in the Reduction of Cardiovascular Events
por: Campbell, Duncan J
Publicado: (2006) -
Effect of a fixed-dose combination of Telmisartan/S-amlodipine on circadian blood pressure compared with Telmisartan monotherapy: TENUVA-BP study
por: Kim, Bong-Joon, et al.
Publicado: (2022) -
Telmisartan Lowers Elevated Blood Pressure in Psoriatic Mice without Attenuating Vascular Dysfunction and Inflammation
por: Wild, Johannes, et al.
Publicado: (2019)